Table 2.
. Binding antibody, neutralizing antibody, and T cell response.
| Characteristic | BNT162b2 | Half-dose mRNA-1273 |
mRNA-1273 | MVC—COV1901 | P value* |
|---|---|---|---|---|---|
| SARS-CoV-2 anti-spike IgG, BAU/mL |
N = 83 | N = 85 | N = 85 | N = 85 | |
| GMC before boost | 35 (30–42) | 36 (31–43) | 38 (32–46) | 42 (35–50) | P = 0.52 |
| GMC after boost | 1133 (971–1323) | 1723 (1521–1952) | 2400 (2067–2788) | 352 (301–411) | P <0.001 |
| Fold change | 32.18 (27.18–38.11) | 47.60 (40.78–55.56) | 63.20 (53.56–74.56) | 8.40 (6.82–10.35) | |
| Surrogate neutralizing antibody by ELISA, IU/mL | N = 83 | N = 85 | N = 85 | N = 85 | |
| GMT before boost | 16 (14–19) | 17 (14–20) | 15 (13–17) | 17 (15–20) | P = 0.17 |
| GMT after boost | 524 (481–573) | 657 (609–708) | 709 (658–764) | 219 (187–256) | P < 0.001 |
| Fold change | 32.27 (27.38–38.04) | 39.75 (33.18–47.61) | 47.71 (41.36–55.03) | 12.69 (10.20–15.79) | |
| Live virus neutralizing antibody (wild type), NT50, IU/mL |
N = 30 | N = 30 | N = 30 | N = 30 | |
| Before boost | 39 (29–51) | 37 (28–47) | 32 (25–42) | 40 (30–54) | P = 0.64 |
| After boost | 1154 (981–1357) | 1673 (1459–1918) | 1607 (1423–1815) | 501 (384–654) | P <0.001 |
| Fold change | 29.81 (24.06–36.93) | 45.53 (36.03–57.53) | 49.97 (38.23–65.31) | 12.34 (8.41–18.10) | |
| Pseudovirus neutralizing antibody (D614G), ID50 | N = 30 | N = 30 | N = 30 | N = 30 | |
| Before boost | 123 (90–167) | 139 (99–194) | 110 (78–156) | 108 (78–149) | P = 0.74 |
| After boost | 3298 (2786–3905) | 4140 (3558–4817) | 5375 (4576–6314) | 1428 (1050–1941) | P < 0.001 |
| Fold change | 26.77 (19.50–36.77) | 29.72 (22.34–39.52) | 48.94 (33.64–71.22) | 13.22 (8.54–20.47) | |
| Live virus neutralizing antibody (alpha), NT50, IU/mL |
N = 30 | N = 30 | N = 30 | N = 30 | |
| Before boost | 20 (18–23) | 20 (18–23) | 20 (18–22) | 23 (19–29) | P = 0.88 |
| After boost | 1566 (1256–1951) | 2022 (1669–2450) | 2351 (2017–2739) | 535 (386–740) | P < 0.001 |
| Fold change | 76.86 (61.57–95.95) | 99.31 (82.74–119.20) | 118.11 (101.52–137.42) | 23.01 (15.97–33.17) | |
| Live virus neutralizing antibody (delta), NT50, IU/mL |
N = 30 | N = 30 | N = 30 | N = 30 | |
| Before boost | 23 (19–27) | 21 (18–25) | 21 (17–25) | 26 (21–33) | P = 0.29 |
| After boost | 1325 (1069–1641) | 1427 (1177–1730) | 1879 (1606–2200) | 624 (441–883) | P < 0.001 |
| Fold change | 57.77 (47.34–70.50) | 73.16 (55.24–96.90) | 97.79 (70.22–136.19) | 23.81 (15.47–36.63) | |
| Live virus neutralizing antibody (omicron), NT50, IU/mL |
N = 30 | N = 30 | N = 30 | N = 30 | |
| Before boost | 17 (17–17) | 17 (17–17) | 17 (17–17) | 17 (17–17) | P = 1.0 |
| After boost | 146 (119–179) | 204 (152–275) | 250 (195–322) | 37 (25–53) | P < 0.001 |
| Fold change | 8.38 (6.82–10.29) | 11.75 (8.73–15.82) | 14.41 (11.22–18.50) | 2.10 (1.44–3.07) | |
| Pseudovirus neutralizing antibody (omicron), ID50 |
N = 30 | N = 30 | N = 30 | N = 30 | |
| Before boost | 10 (7–13) | 10 (8–14) | 13 (10–19) | 8 (6–11) | P = 0.21 |
| After boost | 682 (516–902) | 851 (681–1064) | 1165 (931–1457) | 273 (189–395) | P < 0.001 |
| Fold change | 71.12 (49.97–101.22) | 81.47 (62.39–106.38) | 86.56 (59.86–125.15) | 32.89 (20.11–53.79) | |
| Cellular response, SFU per 2 × 105 PBMCs |
N = 83 | N = 85 | N = 85 | N = 85 | |
| Before boost | 29 (25–34) | 27 (23–31) | 26 (23–30) | 26 (22–30) | P = 0.45 |
| After boost | 89 (80–99) | 105 (94–117) | 109 (99–120) | 84 (74–95) | P = 0.01 |
| Fold change | 3.05 (2.60–3.59) | 3.92 (3.30–4.65) | 4.21 (3.59–4.92) | 3.26 (2.77–3.85) |
Data are GM (95% CI). BAU=binding antibody unit. GMC=geometric mean concentration. GMT=geometric mean titer. ELISA=enzyme-linked immunosorbent assay. NT50= 50% neutralization titer. ID50=50% inhibitory dose. SFU=Spot-forming unit. PBMCs=peripheral blood mononuclear cells.
*P values were reported using Kruskal-Wallis.